RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes
Science Advances · 03.11.2023 · 9 (44)
DOI: 10.1126/sciadv.adf5238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 03.11.2023. Verfasst von Nagesha Guthalu Kondegowda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA 910…. Hauptthemen laut MEDLINE: Osteoprotegerin, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Treatment for type 1 diabetes (T1D) requires stimulation of functional β cell regeneration and survival under stress. Previously, we showed that inhibition of the RANKL/RANK [receptor activator of nuclear factor kappa Β (NF-κB) ligand] pathway, by osteoprotegerin and the anti-osteoporotic drug denosumab, induces rodent and human β cell proliferation. We demonstrate that the RANK pathway mediates cytokine-induced rodent and human β cell death through RANK-TRAF6 interaction and induction of NF-κB activation. Osteoprotegerin and denosumab protected β cells against this cytotoxicity. In human immune cells, osteoprotegerin and denosumab reduce proinflammatory cytokines in activated T-cells by inhibiting RANKL-induced activation of monocytes. In vivo, osteoprotegerin reversed recent-onset T1D in nonobese diabetic/Ltj mice, reduced insulitis, improved glucose homeostasis, and increased plasma insulin, β cell proliferation, and mass in these mice. Serum from T1D subjects induced human β cell death and dysfunction, but not α cell death. Osteoprotegerin and denosumab reduced T1D serum–induced β cell cytotoxicity and dysfunction. Inhibiting RANKL/RANK could have therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA 91010, USA.
- Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Immunology and Theranostics, Arthur Riggs Diabetes and Metabolism Research Institute, City of Hope, Duarte, CA 91010, USA.
- Division of Endocrinology and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna 1030, Austria.
- Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada.
ORCID-Profile: Nagesha Guthalu Kondegowda, Nancy Leon-Rivera, Rosemary Li, Josef M Penninger, Helena Reijonen, Rupangi C Vasavada
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Kondegowda, N. G., Filipowska, J., Do, J. S., Leon-Rivera, N., Li, R., Hampton, R., Ogyaadu, S., Levister, C., Penninger, J. M., Reijonen, H., Levy, C. J., & Vasavada, R. C. (2023). RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes. Science Advances, 9(44). https://doi.org/10.1126/sciadv.adf5238
Vancouver
Kondegowda NG, Filipowska J, Do JS, Leon-Rivera N, Li R, Hampton R, et al. RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes. Science Advances. 2023;9(44). doi:10.1126/sciadv.adf5238
BibTeX
@article{Kondegowda2023,
author = {Kondegowda, Nagesha Guthalu and Filipowska, Joanna and Do, Jeong-Su and Leon-Rivera, Nancy and Li, Rosemary and Hampton, Rollie and Ogyaadu, Selassie and Levister, Camilla and Penninger, Josef M and Reijonen, Helena and Levy, Carol J and Vasavada, Rupangi C},
title = {RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {44},
doi = {10.1126/sciadv.adf5238}
}
EUVIMED